Status:
TERMINATED
Safety Study of Abatacept to Treat Refractory Sarcoidosis
Lead Sponsor:
University of Chicago
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Sarcoidosis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine how safe and effective Abatacept is in treating patients who have progressive pulmonary sarcoidosis.
Eligibility Criteria
Inclusion
- Primary
- Diagnosis of sarcoidosis for at least 1 year with lung disease
- Active disease despite current treatment
- On a stable dose of sarcoidosis treatment with oral steroids, methotrexate, or hydroxychloroquine, for at least 90 days
- Primary
Exclusion
- Previous treatment with Abatacept
- Currently receiving or received within the last 60 days the following: TNFα-inhibitors (infliximab, etanercept, adalimumab)
- Currently receiving or received within the last 30 days the following: cyclosporine, tacrolimus or leflunomide
- Previous treatment of IVIg within the last 6 months
- History of chronic infection that has been active within last 60 days, or herpes zoster within last 6 months, or any infection requiring hospitalization or intravenous medication within last 60 days or oral medication within the last 2 weeks
- History of congestive heart failure
- HIV
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT00739960
Start Date
August 1 2008
End Date
December 1 2008
Last Update
March 23 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Chicago
Chicago, Illinois, United States, 60637